Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy

Table 3 Univariate and multivariate analyses of clinicopathologic factors according to PFS and OS

Factor	n	PFS			OS
Factor	n	Median (months)	Univariate p value	Multivariate p value (95% CI)	Median (months)	Univariate p value	Multivariate p value (95% CI)
Age
≤ 61	59	15.9	0.549		28.5	0.533
> 61	58	16.1			29.9
Sex
Male	79	15.9	0.908		24.1	0.267
Female	38	16.5			32.0
Stage
IIIA	30	19.5	0.306		34.6	0.269
IIIB	75	13.9			26.5
Histology
Squamous	71	15.9	0.740		24.1	0.190
Adeno	39	16.7			34.0
ECOG PS
0	58	18.6	0.078	0.273	37.4	0.002	0.013
1–2	59	14.2		(0.830–1.936)	21.3		(1.145–3.066)
PD-L1
Negative	37	15.9	0.696		29.9	0.830
Positive	80	16.1			28.5
PD-L1
< 50%	82	14.7	0.362		29.9	0.689
≥ 50%	35	19.4			29.8
RT dose
< 60 Gy	22	10.6	0.014	0.019	17.5	< 0.001	0.001
≥ 60 Gy	95	18.6		(0.321–0.905)	32.0		(0.218–0.667)
NLR pre
< 5	87	17.2	0.532		34.0	0.059	0.087
≥ 5	23	13.8			21.4		(0.933–2.810)
NLR post
< 5	48	19.5	0.408		34.6	0.120
≥ 5	65	13.5			24.1
CRP pre
≤ 10	54	20.7	0.093	0.217	37.5	0.063	0.105
> 10	56	13.3		(0.855–1.990)	24.1		(0.919–2.416)
CRP post
≤ 10	74	19.5	0.009	0.221	34.0	0.005	0.250
> 10	41	12.5		(0.842–2.099)	20.3		(0.808–2.265)

Results with values of p < 0.2 in univariate analysis were calculated in multivariate analysis. A p-value less than 0.05 was considered statistically significant
ECOG PS Eastern Cooperative Oncology Group performance status, n number, PFS progression free survival, OS overall survival, RT radiotherapy, NLR neutrophil lymphocyte ratio, CRP C reactive protein, pre pre-treatment, post post-treatment

ISSN: 1748-717X